

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

**STA Regorafenib for treating advanced gastrointestinal
stromal tumours**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final appraisal determination

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
|---|

The potential issues raised during scoping were not considered specific equalities issues.
--

- | |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
|--|

The committee noted comments suggesting that there may be equity issues from variation in access to regorafenib within the UK. The committee agreed that this does not represent a potential equality issue

- | |
|--|
| 3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these? |
|--|

No additional equalities issues were identified by the committee.

- | |
|--|
| 4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? |
|--|

If so, what are the barriers to, or difficulties with, access for the specific group?

Regorafenib is only recommended for people who have an ECOG performance status of 0 to 1. For this reason, the committee concluded that healthcare professionals should take into account any physical, sensory or learning disabilities, or communication difficulties that could affect ECOG performance status and make any adjustments they consider appropriate.

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

See above.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

The committee included the following in section 1.2 of the recommendations:

“When using ECOG performance status, healthcare professionals should take into account any physical, sensory or learning disabilities, or communication difficulties that could affect ECOG performance status and make any adjustments they consider appropriate”

7. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

Yes, see section 3.17 of the final appraisal determination.

Approved by Associate Director (name): Helen Knight

Date: 19/09/2017

Technology appraisals: Guidance development

Equality impact assessment for the single technology appraisal of regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours

Issue date: November 2017